Please complete the CAPTCHA to continue
@alz-pharma.com
✓
6 phones found area 390, 508, and 315
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Michael Culler is listed as CSO for Amolyt Pharma. Scientific founder and Chairman, Scientific Advisory Board for Tiburio Therapeutics at Amolyt Pharma, based in Greater Boston, United States. AeroLeads shows a work email signal at alz-pharma.com, phone signal with area code 390, 508, 315, and a matched LinkedIn profile for Michael Culler.
Michael Culler previously worked as Chief Scientific Officer at Amolyt Pharma and Scientific Founder, and Chairman of the Scientific Advisory Board at Tiburio Therapeutics. Michael Culler holds Postdoctoral Training, Neuroendocrinology from Tulane University School Of Medicine.
This section adds company-level context without repeating Michael Culler's masked contact details.
AeroLeads found 1 current-domain work email signal for Michael Culler. Compare company email patterns before reaching out.
Chief Scientific Officer for Amolyt Pharma. Scientific founder and Chairman of the Scientific Advisory Board for Tiburio Therapeutics. Co-founder of Rhythm Pharmaceuticals. Led the pre-clinical programs that produced the key development assets for Rhythm (relamorelin and setmelanotide: Imcivree®), Radius Pharma (abaloparatide: Tymlos®) and Tiburio Therapeutics (TBR-760 and TBR-065). Former Vice President, Endocrinology Research for Ipsen. While at Ipsen, led programs in diverse endocrine/metabolic areas that resulted in six compounds reaching clinical development. Prior to joining industry, conducted basic research in neuroendocrine physiology as a staff scientist at the National Institutes of Health, and as a postdoctoral fellow at Tulane University School of Medicine. Internationally recognized expert in endocrinology, metabolic disorders, endocrine oncology, and peptide therapeutics, with over 200 publications and 22 patents. Member of the Prohibited List Expert Committee of the World Anti-Doping Agency (WADA)
Listed skills include Pharmaceutical Industry, Endocrinology, Biotechnology, Oncology, and 7 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Ecully, Fr
Alizé Pharma is specialized in developing innovative therapeutic peptides for the treatment of rare endocrine and metabolic diseases. Our portfolio includes a best-in-class parathyroid hormone (PTH) analog uniquely designed for the treatment of hypoparathyroidism, and a small peptide antagonist of the growth hormone receptor for the treatment of acromegaly.
Tiburio is dedicated to advancing novel treatments for serious neuroendocrine disorders such as non-functioning pituitary adenoma (NFPA). Tiburio is currently developing TBR-760, a dopamine-somatostatin chimeric compound, for the treatment of non-functioning pituitary adenoma (NFPA). Tiburio’s development stage pipeline also includes TBR-065, a novel therapy for other rare neuroendocrine diseases.
Providing expert consultation for research, development, and related activities in endocrinology, neuroendocrinology, and metabolic disease for multiple biotechnology and large-pharma clients
Boulogne Billancourt, Fr
Vice President, Endocrinology Research (2008 - 2017)Senior Director and Head of Endocrinology Research (2002 - 2008)Director and Head of Biological Research (1995 - 2002)• Directed multiple, successful research programs in diverse endocrine/metabolic indications producing five compounds currently in or completing clinical development.• PTHrP Analog (BIM-44058: Abaloparatide) for Osteoporosis (Market Approval: Tymlos®)• GLP1 Analog (BIM-51077: Taspoglutide) for Diabetes (Phase III Clinical)• Ghrelin Analog (BIM-28131: Relamorelin) GI motility/Cachexia (Phase III Clinical)• MC4 Agonist (BIM-22493: Setmelanotide) Obesity/Diabetes (Market Approval: Imcivree®)• Somatostatin-Dopamine Chimeric Molecule (BIM-23B065) Pituitary Tumors (Phase I Clinical)• Successfully managed efforts, and delivered presentations to out-license assets for development, and to secure venture capital funding. Co-founded Rhythm Pharmaceuticals for development of relamorelin and setmelanotide.• Built and maintained extensive network of external academic and industry collaborators to accelerate programs by taking advantage of established models and expertise. Source of new targets, concepts and valuable opinions in diverse endocrine areas.
Research: Endocrine-immune interactions, hormonal basis of affective disorders, antisera and immunoassay development
Research Triangle Park, Nc, Us
Research: Endocrine communication within hypothalamic-pituitary-gonadal axis, pulsatile hormone secretion, immunoneutralization of endogenous hormones, antisera and immunoassay development.
Mentor: Dr. Akira ArimuraResearch: Design and development of bio- and immunoassays for target neuroendocrine factors. Member of team for isolation and characterization of novel brain hormones; successful isolation, sequencing and characterization of PACAP. Conducted research into intracellular mechanisms of hormone action.
Quick answers generated from the profile data available on this page.
Michael Culler works for Amolyt Pharma.
Michael Culler is listed as CSO for Amolyt Pharma. Scientific founder and Chairman, Scientific Advisory Board for Tiburio Therapeutics at Amolyt Pharma.
AeroLeads has found 1 work email signal at @alz-pharma.com for Michael Culler at Amolyt Pharma.
AeroLeads has found 6 phone signal(s) with area code 390, 508, 315 for Michael Culler at Amolyt Pharma.
Michael Culler is based in Greater Boston, United States while working with Amolyt Pharma.
Michael Culler has worked for Amolyt Pharma, Tiburio Therapeutics, Culler Consulting, Llc, Ipsen, and Johnson And Johnson Immunobiology Research Institute.
You can use AeroLeads to view verified contact signals for Michael Culler at Amolyt Pharma, including work email, phone, and LinkedIn data when available.
Michael Culler holds Postdoctoral Training, Neuroendocrinology from Tulane University School Of Medicine.
Michael Culler is listed with skills including Pharmaceutical Industry, Endocrinology, Biotechnology, Oncology, Clinical Development, Molecular Biology, Drug Development, and Drug Discovery.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts